Le Lézard
Classified in: Health
Subject: AWD

CleanCisiontm Earns Reader's Choice Award Across All Categories and Bronze Medal in the Emergency Room and Operating Room Technology Category in 2018 Medical Design Excellence Awards Competition


NEW YORK, June 12, 2018 /PRNewswire/ -- Prescient Surgical, innovator of advanced tools and technologies to fight and defend against the sources of surgical site infection, announced that its CleanCisiontm active cleansing technology, earned the 2018 Medical Device Excellence Award (MDEA) Bronze Medal in the ER and OR tools category. CleanCision also earned the overall MDEA Reader's Choice Award, which spans all categories in the competition.

CleanCisiontm is the first in a new FDA device class of irrigating wound protectors developed to retract the surgical incision, provide abdominal access, and consistently and continuously irrigate the wound edge with a surgeon-selected fluid therapy to actively fight and remove the root cause of surgical site infection--wound contamination--without disrupting current surgical practice.

Developed and designed collaboratively with surgeons and infection control experts, the first-in-class CleanCision system continuously clears harmful bacteria from surgical incisions by combining wound protection and irrigation into an intuitive and easy-to-use retraction system. Unlike traditional methods, which cannot continuously and consistently clear contamination from the surgical site, CleanCision has been shown to reverse and reduce these pervasive sources of infection, clearing harmful bacteria throughout surgery when the threat of wound contamination is at its highest.1 

"We share this award with the surgeons and infection control experts who collaborated with us to create an intuitive design that is filling a critical gap in hospital surgical site infection control programs," said Jonathan Coe, president, CEO and co-founder of Prescient Surgical.

The CleanCisiontm System Defends Against the Root Cause of Surgical Site Infection
Wound contamination is the root cause of SSI, yet after nearly a decade of national SSI focus, hospital teams still struggle to gain control over this invisible threat. Surgical technologies have not evolved to adequately eliminate pervasive intraoperative contamination, leaving patients vulnerable to infection. The rate of SSI can be as high as 15 to 30 percent in certain high-risk, clean-contaminated, and contaminated procedures such as colorectal surgery.2 

About the MDEA Awards 
The MDEA is the premier awards program for the medical technology industry, recognizing significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. For more information go to http://mdeawards.mddionline.com/

About Prescient Surgical
Based in San Carlos, Calif., Prescient Surgical, Inc. is a medical device innovator that makes advanced tools and technologies to fight and defend against the sources of surgical site infection. The company was conceived at the Stanford Byers Center for Biodesign and accelerated at Stanford StartX Med and the Fogarty Institute for Innovation.

For more information contact [email protected]

Related links
www.prescientsurgical.com 
Twitter: https://twitter.com/PrescientSurg 
LinkedIn: https://www.linkedin.com/company/prescient-surgical/

1 Papaconstantinou, H.T., Ricciardi, R., Margolin, D.A. et al. (2018) 'A Novel Wound Retractor Combining Continuous Irrigation and Barrier Protection Reduces Incisional Contamination in Colorectal Surgery', World J Surg (Published online March 9, 2018) DOI: 10.1007/s00268-018-4568-z.

2 Zywot A, Lau CSM, Stephen Fletcher H, Paul S. Bundles Prevent Surgical Site Infections After Colorectal Surgery: Meta-analysis and Systematic Review. J Gastrointest Surg. 2017.

Prescient Surgical Logo (PRNewsfoto/Prescient Surgical)

SOURCE Prescient Surgical


These press releases may also interest you

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...

at 16:19
Aflac Incorporated announced today that it will release first quarter 2024 financial results after the market closes on May 1, 2024. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...



News published on and distributed by: